Microalbuminuria is considered a marker of heightened risk for cardiovascular events. We examined cardiovascular risk factors, including inflammatory cytokines, which contribute to urinary albumin excretion (UAE) in a cross-sectional study of African Americans aged 18-49 years. Measurements included a timed overnight urine collection for UAE, blood pressure (BP), body mass index, glucose, lipids, insulin and inflammatory cytokines. Non-normally distributed variables were log transformed for analysis using multiple linear regressions. Data were obtained from 488 participants with mean age 37.8 years; 50% were obese, 42% had hypertension. Log UAE correlated significantly with systolic BP (SBP) (geometric mean ratio ¼ 1.011; 95% confidence interval 1.003-1.019). When subjects were stratified into four UAE groups, the only variables significantly different between groups were SBP (P ¼ 0.013) and diastolic BP (P ¼ 0.036). There were no statistically significant associations with obesity, metabolic parameters, insulin resistance or any inflammatory cytokines identified. In young, relatively healthy, African Americans, BP level is significantly associated with levels of UAE even below the threshold for microalbuminuria. The presence of diabetes and insulin resistance in the absence of high BP did not seem to contribute significantly to UAE in this cohort.
Introduction
The significance of urinary albumin excretion (UAE) in chronic kidney disease has been well established. More recent studies have investigated a relationship between UAE and cardiovascular disease. Several large clinical trials have demonstrated an association between UAE and relative risk for major cardiovascular events and all-cause mortality. 1, 2 Moreover, clinical trials designed to lower UAE have reported outcome benefit with a reduction in cardiovascular events. 3 It has been proposed that increased UAE, in the absence of chronic kidney disease, may be a marker of vascular or endothelial injury and a predictor of future cardiovascular events.
The clinical threshold for elevated UAE has been designated 'microalbuminuria' and is generally defined as 20-200 mg min À1 or 30-300 mg per g creatinine (CR). UAE 4300 mg per g CR is considered to be clinical proteinuria. The definition of microalbuminuria was derived from several small studies of diabetics. 4 Normal UAE may actually be much lower than 29 mg per g CR. On the basis of the population data from the National Health and Nutrition Examination Survey (NHANES), mean UAE in adults was 12.3 mg per g CR. 5 In another large study of young adults, the median UAE was 2.3 mg per g CR. 6 Although microalbuminuria defines a clinically significant threshold for UAE, the association of UAE with cardiovascular risk may be linear and become manifest below 30 mg per g CR. Data from several clinical trials have identified an increase in adverse cardiovascular outcomes at levels of UAE below 30 mg per g CR. 1, 7, 8 In addition to the large clinical trials designed to measure outcomes, smaller studies have identified an association of UAE with cardiovascular disease risk factors, including high blood pressure (BP), [9] [10] [11] metabolic syndrome, 12 impaired glucose tolerance, 10 insulin resistance, 13 and dyslipidemia 12 and with biomarkers of inflammation.
14 Increased UAE has also been associated with proinflammatory markers [14] [15] [16] and arterial stiffness [17] [18] [19] [20] in older adults and in adults with cardiovascular disease and diabetes. The clinical data demonstrate a consistent significant association of increases in UAE with progression in cardiovascular and renal injury. The significance of UAE in younger relatively healthy populations is less clear.
African Americans have disproportionately greater rates of hypertension, diabetes, chronic kidney disease and cardiovascular events compared with other ethnic/racial groups. Data that demonstrate the association of UAE and microalbuminuria with cardiovascular and renal events have been derived from studies on older adults with established cardiovascular disease or diabetes. In this study we sought to determine if this association is detectable in a vulnerable population (African Americans) before the development of clinical diabetes or clinically evident cardiovascular disease other than high BP. Therefore, we conducted a crosssectional study in young adult relatively healthy African Americans to determine the cardiovascular risk factors, including biomarkers of inflammation, which contribute to UAE. We also sought to determine if there were detectable associations between risk factors or inflammatory biomarkers and UAE below the threshold for microalbuminuria.
Methods

Study population
A cross-sectional study was conducted on relatively healthy African-American adults aged 18-49 years. The goal of the overall study was to investigate interactions of obesity and high BP on risk factors in a vulnerable population before clinical manifestations of cardiovascular disease or diabetes. Participants were recruited in urban Philadelphia through local advertisements. Enrollment included individuals without and with obesity (body mass index (BMI) X30 kg m À2 ), and individuals with and without hypertension. Participants with clinically evident chronic cardiovascular, renal or metabolic diseases were excluded. Criteria for exclusion from enrollment included secondary hypertension, known diagnosis of diabetes type I or type II, pregnancy, known renal or cardiac disease, known autoimmune disease, thyroid disease, sickle cell disease, anorexia nervosa, polycystic ovary syndrome and the use of steroids. The study protocol was approved by the Institutional Review Board of Thomas Jefferson University. Written informed consent was obtained from each participant at enrollment.
Study procedures
Each participant was given instructions to collect a timed overnight urine sample on the morning of the visit to the clinical research centre. Data on health status, medication use and health-related behaviours were obtained by participant self-report. Clinical assessment consisted of anthropometric measurements (height and weight, waist circumference) and BP. BMI was calculated as weight (kg) divided by height squared (m 2 ). BP measurements were obtained from each subject following a 10-min rest period in a seated position. The average of four successive measurements of systolic blood pressure (SBP) and diastolic blood pressure (DBP) was used as the BP value for each participant.
An oral glucose tolerance test was conducted after a 12-hour overnight fast. A fasting blood sample was obtained for plasma glucose, insulin and lipids. In addition to traditional risk factors, we also measured a panel of cytokines considered to be biomarkers of inflammation. Samples of fasting plasma were also prepared and stored for later assay of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), plasminogen-activator inhibitor-1, tumour necrosis factor-a (TNF-a), tumour necrosis factor-a receptor (TNF-aR) and adiponectin. Following the ingestion of 75 g of glucose solution (Glucola; Ames Diagnostics, Elkhart, IN, USA), blood samples were then obtained at 30, 60 and 120 min post-ingestion and assayed for plasma glucose and insulin concentrations. Plasma glucose concentration was analysed with the glucose oxidase technique (YS Model 27; Glucostat, Yellow Springs, OH, USA). Plasma insulin concentration was determined using a solid phase radioimmunoassay (Coat-a-Count; Diagnostic Products, Los Angeles, CA, USA). Coefficients of variation for intra-and inter-assay variability for glucose and insulin assays were o5%. Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA). 21 Fasting lipids including total cholesterol, lowdensity lipoprotein, high-density lipoprotein and triglycerides were measured using the Hitachi 704 standard enzymatic method in the Lipid Laboratory of Thomas Jefferson University. UAE was measured by enzyme-linked immunosorbent assay (Exocell, Philadelphia, PA, USA). UAE was corrected for CR and expressed in mg per g CR. Our laboratory control measures indicate that these assays are highly reliable with consistently low coefficients of variation (o5%). All assays for the cytokines were performed by enzyme-linked immunosorbent assay in duplicate using commercially available kits. Kits for adiponectin, IL-6, TNF-a, TNF-aR and hsCRP were obtained from R&D Systems (Minneapolis, MN, USA). The kits for plasminogen-activator inhibitor-1 were obtained from Aniara (Mason, OH, USA). The coefficient of variation for these assays was consistently o10% and most o6%.
Statistical analyses
Continuous variables available for analysis of UAE included age, BMI, SBP, fasting glucose, fasting insulin, high-density lipoprotein, low-density lipoprotein, HOMA, adiponectin, hsCRP, IL-6, plasminogen-activator inhibitor-1, TNF-a and TNF-aR. Categorical variables included gender, taking hypertension medication (yes or no), smoking status (response to 'do you smoke cigarettes? yes or no') and alcohol consumption (response to 'do you drink alcohol? yes or no'). Because of the skewed distribution of the UAE data, UAE was log transformed for statistical analysis as a continuous dependent variable. The data for fasting glucose, fasting insulin, IL-6, TNF-aR and hsCRP also had skewed distributions and were log transformed for analysis. For the adipokine variables, the geometric mean and the first and third quartiles (Q1, Q3) on the original scale are presented as measures of central tendency and dispersion.
For summary purposes, subjects were stratified into groups on the basis of BMI, BP, plasma glucose and metabolic syndrome. BMI status was classified as obese (X30 kg m À2 ), overweight (25-o30 kg m À2 ) and normal (o25 kg m À2 ). BP groups included hypertensive, prehypertensive and normal. Hypertensive was defined by BP X140/90 mm Hg or taking antihypertensive medication. Prehypertensive was defined by BP 120-139/80-89 mm Hg. Subjects were stratified into three groups on the basis of the fasting and 2-h glucose: diabetic, prediabetic and normal. Diabetic was defined by fasting blood glucose 4125 mg per 100 ml or 2-h glucose 4199 mg per 100 ml, and prediabetic was defined by fasting blood glucose 100-125 mg per 100 ml or 2-h glucose of 140-199 mg per 100 ml. Metabolic syndrome was defined as having met any three of the following five criteria: waist circumference X102 cm (for males), X88 cm (for females); SBP X130 mm Hg or DBP X85 mm Hg or taking antihypertensive medication; high-density lipoprotein o40 (for males), o50 (for females); triglycerides X150 mg per 100 ml; fasting glucose X110 mg per 100 ml. 22 To investigate linear relationships between continuous UAE and other study variables, we fit a multiple linear regression model to log UAE as a dependent variable. Model parameters for independent variables from this model are presented as geometric mean ratios, which individually represent the independent multiplicative increase in UAE, on its untransformed scale, per unit increase of a particular independent variable. To further test for the association between risk factors or cytokines with UAE, we conducted an analysis on groups stratified by UAE: p5 mg per g CR, 5-10 mg per g CR, 11-20 mg per g CR and 420-299 mg per g CR. Subjects with UAE X300 mg per g CR were excluded from analysis. One-way analysis of variance models were used to determine whether the means of risk factors or cytokines were different across the four UAE groups.
We used t-tests assuming unequal variances to compare risk factor means and cytokine means between subjects with microalbuminuria (30-299 mg per g CR) and those without clinical microalbuminuria (o30 mg per g CR).
The multiple linear regression model was adjusted for at least age, gender, BMI, SBP, taking antihypertensive medication, smoking history and alcohol use. Other potential predictors could be dropped from the full model, containing all covariates, by backward selection. Any of these potential predictors (including fasting glucose, fasting insulin, HOMA, adiponectin, hsCRP, IL-6, plasminogen-activator inhibitor-1, TNF-a and TNFaR, as well as two-and three-way interactions between BMI, SBP and taking antihypertensive medication), which were not found to contribute to the predictive ability or adjustment of model predictors, were eliminated in a stepwise manner from the model. To limit bias in the final model, the criterion for eliminating a variable from the model was set at a ¼ 0.20 for the potential predictor having the largest Wald statistic P-value at each step. 23 
Results
A total of 503 subjects were enrolled in the study. Fifteen subjects were excluded from data analyses. Five subjects were excluded due to suspected intrinsic renal disease based on UAE X300 mg per g CR or serum CR 41.4 mg per 100 ml. Cases (N ¼ 10) with incomplete data were also excluded. Data from 488 subjects were analysed. UAE ranged from 0.1 to 228.5 mg per g CR for the entire cohort of 488 subjects. Forty seven had microalbuminuria (30-299 mg per g CR), and 441 subjects had a UAE which was o30 mg per g CR. . Fifty percent of subjects were obese and 28% were overweight. There were significantly more females classified as obese or overweight compared with males (Po0.001). Mean SBP for the entire cohort was 121.9±17.1 mm Hg (range 89-190 mm Hg). DBP was 75.6 ± 12.3 mm Hg (range 48-121 mm Hg). Forty-two percent (n ¼ 206) had hypertension by the defined measures, and 22% (n ¼ 108) were classified as prehypertensive. Thirtytwo percent (n ¼ 156) reported taking antihypertensive medication. Males were more likely than females to be classified as hypertensive or prehypertensive (P ¼ 0.002). Mean fasting glucose was 103.7 mg per 100 ml (range 68-287 mg per 100 ml). Nine percent of subjects (n ¼ 45) were diabetic, and 29% (n ¼ 143) were prediabetic. There was no significant difference in diabetic status between males and females. Twenty-six percent of subjects (n ¼ 129) had metabolic syndrome, which was associated with gender, as more women (35%) than men (18%) met the diagnosis criteria (Po0.001). Sixty-two percent (n ¼ 302) of participants reported smoking, and 47% (n ¼ 47) admitted to alcohol use. Alcohol use was significantly more common in males (P ¼ 0.005). The amount of alcohol consumption was not quantified.
A multiple linear regression model of log UAE showed that SBP was significantly associated with increasing UAE (geometric mean ratio ¼ 1.011; 95% confidence interval 1.003-1.019) after adjusting for nonsignificant covariates, including age, gender, smoking, alcohol use, BMI, hypertension medication use, PAI1, TNF-a, hsCRP, triglycerides, and an interaction between BMI and hypertension medication. This suggests that for each 10 mm Hg increase in SBP, the expected UAE will increase by 11.6%.
To examine the data on risk factors and cytokines below the clinical threshold for microalbuminuria, we compared unadjusted means across the four stratified UAE groups. The data are presented in Table 2 . Almost half of the subjects (n ¼ 224) had a UAE p5 mg per g CR. The only variable that was significantly different between the UAE groups was BP (P ¼ 0.013 for SBP and P ¼ 0.036 for DBP). There were no statistically significant differences between groups in BMI, metabolic parameters, including HOMA (insulin resistance) or any cytokines.
The results of the analyses in which we compared unadjusted risk factor means and cytokine means among the 47 cases with microalbuminuria and with the 441 subjects without microalbuminuria are Urinary albumin excretion KE Ussai et al provided in Table 3 . Again, SBP was significantly higher in the microalbuminuria group compared with the normal group (UAE o30 mg per g CR); 126.9 mm Hg vs 121.4 mm Hg (P ¼ 0.03). DBP was also significantly higher in the microalbuminuria group, 79.9 vs 75.1 mm Hg (P ¼ 0.013). There were no significant differences between these two groups in BMI, metabolic parameters, including HOMA (insulin resistance) or any cytokines.
Discussion
The results of our study show that in a population of young, relatively healthy, African Americans, BP level is significantly associated with levels of UAE even below the clinical threshold for microalbuminuria. The presence of diabetes and insulin resistance in the absence of high BP did not seem to contribute significantly to UAE in this cohort. An independent association between inflammatory cytokines and UAE was not detected. The association of hypertension with elevated levels of UAE has been well established. In 1992, Gerber et al. 24 reported on data from a large crosssectional study that compared hypertensive and normotensive subjects. They found that hypertensives had significantly higher levels of UAE compared with normotensives (Po0.001). Those with hypertension had a mean UAE of 21.5 mg every 24 h and those without hypertension had a mean UAE of 6.6 mg every 24 h. Subjects with hypertension were also significantly more likely to have a UAE X15 mg every 24 h than subjects without hypertension. The presence of microalbuminuria (UAE 430 mg every 24 h) was significantly more common in hypertensive individuals as well. Interestingly, the group with hypertension had mean SBP and DBP within the range considered mild hypertension (or stage 1 hypertension by Joint National Commision 7 guidelines), 25 with mean SBP of 149.2 mm Hg and mean DBP of 99.7 mm Hg. This finding suggests the presence of renal injury, and perhaps vascular injury, even with mildly elevated BP.
The findings of our study regarding BP are consistent with data from the CARDIA (Coronary Risk Development in Young Adults) study. 26 In this 15-year observational cohort study of 2582 subjects, the authors compared BP measured at years 0, 7 and 10 with UAE measured at years 10 and 15. Mean UAE for each participant was calculated from the measurements at both years 10 and 15. Subjects were stratified into five groups on the basis of BP at year 10. Only the highest level BP group had hypertension by clinical definition (BP X140/ 90 mm Hg and/or taking antihypertensive medication). BP levels in the remaining four groups were o140/90 mm Hg. UAE was significantly and positively associated with BP group (Po0.001) following adjustment for age, gender and fasting glucose. When the same data were analysed with BP as a continuous variable, the authors also found that with each s.d. increase of SBP and DBP, the odds ratio for higher UAE increased significantly. High normal BP was significantly associated with increased odds of having microalbuminuria compared with optimal BP (odds ratio 2.13, 95% confidence interval, 1.51-3.01). Although the authors' definition of microalbuminuria is lower than the usual clinical threshold for microalbuminuria, the study demonstrates that higher levels of UAE are associated with higher levels of BP. The Bogalusa Heart Study, 28 which observed 2122 children into young adulthood, demonstrated that, in the African-American subgroup (n ¼ 678), microalbuminuria, defined by UAE X30 mg l À1 , in adulthood was significantly associated with higher levels of SBP and DBP in adulthood and also with higher levels of DBP during childhood. No significant association of childhood BP with adult microalbuminuria was detected in white subjects. In this study, it is noteworthy that participants with known hypertension or diabetes were excluded from the data analyses. Overall, adult African Americans had higher UAE than Caucasians, and African-American males had higher BPs than Caucasian males during childhood.
In our cohort of young adult African Americans, an association between diabetes and UAE was not detected. This finding is not consistent with previous reports. The CARDIA study 26 reported that fasting glucose at year 10 correlated significantly with UAE. Participants designated diabetic (fasting serum glucose X126 mg per 100 ml or taking diabetic medication) and participants with impaired glucose tolerance (fasting serum glucose 110-125 mg per 100 ml) had significantly higher levels of UAE compared with participants with normal fasting glucose (Po0.0001 and 0.007, respectively). The odds ratio of having a higher level of UAE for subjects with diabetes was 10.91 (confidence interval 5.80-20.5) compared with those with normal fasting glucose. We were not able to replicate this finding in our study. Our sample size was smaller than the CARDIA study; however, we were not underpowered to detect an odds ratio of 10.91. We excluded known diabetics from enrollment in our study, whereas diabetes was not an exclusion criterion in CARDIA. In our study, those designated diabetic were newly identified on the basis of the results of the oral glucose tolerance test.
It has been proposed that elevations in UAE, in the absence of renal disease, may reflect a response to inflammatory injury. We did not detect statistically significant associations between UAE and proinflammatory cytokines or the anti-inflammatory cytokine adiponectin in our cohort of young adult African Americans. We selected a panel of inflammatory biomarkers that have been previously reported to be associated with metabolic syndrome [29] [30] [31] and cardiovascular injury. 32 We also measured adiponectin because it is considered to be a protective biomarker with lower levels associated with inflammation, obesity and diabetes. 33 It is surprising that we could not detect an association of hsCRP with UAE in our cohort. As seen in Tables  2 and 3 , over 25% of participants in each UAE group had hsCRP levels greater than 3 mg per 100 ml. However, there were no differences in geometric means for hsCRP between the UAE groups. Similar patterns were present for the other cytokines with no differences between UAE groups. It is possible that in this cohort of young African Americans the increase in UAE reflects a renal response to increased BP, and elevated hsCRP reflects a response to some other risk factor such as obesity.
There are some limitations to our study. The interpretation of our data is limited by the crosssectional design of the study. Although a significant association between BP level and UAE in the young adult African Americans was identified, a cause and effect relationship cannot be assumed. A prospective study with long-term follow-up would provide further insights on causal relationships. Another limitation is that the study group was restricted to African Americans. Therefore, the results may not be generalizeable to other populations. Also, half of the subjects were obese, making this a study sample particularly at risk for hypertension and diabetes, and the cardiovascular comorbidities associated with those diseases. However, the rates of obesity in our cohort are consistent with current population data on African Americans. Although this was a generally healthy cohort, more than half of the subjects did not have optimal BP. Overall, 42% were hypertensive, 22% were prehypertensive and approximately one-third were taking antihypertensive medication at the initial evaluation.
The unique contribution of this study is the finding that a significant positive relationship is present between BP level and UAE. This association is detectable in young African Americans and is detectable below the current threshold for microalbuminuria. Despite the presence of substantial obesity and other risk factors in this cohort, high BP was the only risk factor that contributed significantly to UAE. A strength of our study is that we examined a large cohort of young adult African Americans who were relatively healthy. Most previous reports on the relationship of UAE to cardiovascular risk have been conducted in patients with established cardiovascular disease or diabetes. Other than high BP, our cohort did not have previously diagnosed cardiovascular disease or diabetes, and only 9% were found to have diabetes during the data collection. Hypertension and chronic kidney disease progressing to end-stage renal disease affect African Americans disproportionately. Our findings in this study support the importance of detection and treatment of high BP, especially in an ethnic group at heightened risk for accelerated cardiovascular and renal disease.
